GA HB1033

Requires health benefit policies issued or renewed on or after July 1, 2026 to cover FDA-approved treatments for Alzheimer's disease and related dementias, as well as diagnostic testing including biomarker testing, diagnostic imaging, and cerebrospinal fluid analysis

Prohibits insurers from using step therapy protocols or other utilization management practices that unreasonably delay or deny medically necessary biomarker testing or Alzheimer's treatments

Mandates at least one diagnostic test per covered individual per year without any cost sharing requirement, with overall cost sharing capped at federal out-of-pocket limits for essential health benefits

Requires insurers to provide timely access to in-network providers within reasonable geographic proximity; if unavailable, insurers must cover out-of-network providers at in-network rates and reimburse reasonable travel costs

Establishes annual reporting requirements beginning July 1, 2027, with insurers reporting claims data on approvals, denials, cost sharing amounts, and prior authorization processing times to the Insurance Commissioner